prandd

Marinomed extends the range of Marinosolv applications

• Preclinical studies show promising results with new compounds like mometasone, fluticasone and fluorometholone • Potential for developments in allergy, asthma, and ophthalmology • Marinosolv® facilitates the combination of active ingredients Vienna (Austria), March 9th 2020. Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, has achieved promising results for further areas of…

Marinosolv technology successfully used in preclinical study in severe eye disease Neurotrophic keratopathy

Marinosolv®identified as a feasible aqueous drug carrier with distinct advantages in eye drops  Manifold scope of application for Marinosolv®confirmed Vienna (Austria), February 6th, 2020.Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, and the renowned University of Utah have published scientific investigations that provide initial evidence for further significant benefits of the…

Antioxidant Does Not Withstand Oxygen: Storability of Vegetable Carotene Severely Affected by Oxygen in Air

EQ BOKU’s high-tech equipment at the University of Natural Resources and Life Sciences, Vienna enables precise analysis of factors influencing the storability of natural colouring concentrates. Vienna, 31 July 2019 – The shelf life of vegetable carotenoids when stored in powdered form is severely affected by oxygen in the storage environment – an effect that…

EU Healthcare Systems: a Reallocation Of Resources Is Urgently Needed

Turning away from “low-value” (waste, overuse) towards “high-value” health care is critical for the sustainability of solidarity-based healthcare systems. The Ludwig Boltzmann Institute for Health Technology Assessment is represented on the European Expert Panel. Vienna, 11. July 2019 – On behalf of the European Commission, international health experts are now making a series of recommendations…

Investors Support Phage Therapy: Novel Approach to Solve the Antibiotics Crisis Receives Further Millions

Vienna (Austria), 27 June 2019: Austrian biotech company PhagoMed Biopharma GmbH successfully completed another financing round. PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections. Investors provided further EUR 1.5 million in equity investments to support this novel approach to tackle the antibiotics crisis. The…

Psychological intervention study: even brief abstinence from social media causes withdrawal symptoms

Researchers from Karl Landsteiner University of Health Sciences identify addiction-like behaviour after time away from social media Krems (Austria), 14 November 2018 – In many cases, just a seven-day break from social media platforms such as Facebook and WhatsApp is sufficient to induce withdrawal symptoms like those caused by addictive substances. This is the conclusion…

Europe and USA: agreement on definition and diagnosis of specific form of high blood pressure

Physician from Karl Landsteiner University of Health Sciences plays a part in global consensus-building process Krems (Austria), 6 November 2018 – A transcontinental agreement was recently reached on the definition and diagnosis of a particular form of high blood pressure. Until now, it was difficult to outline a generally accepted set of symptoms – and…

Donor Organs on Demand: Research Looks at Lifelike Organ Models Produced on 3D Printers

Biomedical engineers from Karl Landsteiner University of Health Sciences in Krems launch project focused on 3D printing of tissue models Krems, 02 October 2018 – A research project recently initiated at Karl Landsteiner University of Health Sciences aims to produce organ models with realistic material properties. These biological replicas will mainly be deployed in research…

On the “shelf life” of water: Hot on the trail of the biostability of water using state-of-the-art DNA and cell analysis

Karl Landsteiner University of Health Sciences in Krems launches project to study the growth of water-based microorganisms  Krems (Austria), 9 August 2018 – In order to better understand and assess the quality of ground and spring water, state-of-the-art methods from the fields of molecular biology and microbiology, as well as chemical high-performance analytics are now…

Clinical Results of Neurodegenerative Study

AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as well as Immunogenicity for PD01A in Early MSA patients AFFITOPEs® PD01A and PD03A Safe and Well Tolerated: Primary Endpoint of Phase I Study Met Immune Response against AFFITOPE® PD01A and Alpha-Synuclein Seen in…